About Cavernoma

Overview
A cavernoma, also known as a cavernous hemangioma or cavernous malformation, is a collection of malformed blood vessels. It is a mass made up of small capillaries (blood vessels that connect arteries to veins) and venules (small veins) that create lesions in the central nervous system (CNS). Cavernomas can be present from birth and are usually diagnosed after death during autopsy or incidentally on imaging scans. They can occur anywhere in the CNS. Cavernomas have the potential for growth and are at risk of rupture, which can cause recurrent bleeding. Cavernomas can be recognized by the presence of hemosiderin depositions, which are due to leaky blood vessels and the breakdown of red blood cells. Hemosiderin depositions can be observed on magnetic resonance imaging (MRI) scans. The prevalence and progression of cavernomas remain poorly understood, creating challenges in their management and treatment decisions.
Causes and Risk Factors

Cavernomas are clusters of abnormal blood vessels found in the central nervous system (CNS). The causes of cavernoma are not fully understood, but some risk factors have been identified.

Risk factors of a cavernoma include:

  • Genetic predisposition: Certain genetic mutations or family history of cavernomas may increase the risk.
  • Age: Cavernomas can occur at any age, but they are more commonly diagnosed in adults.

It's important to note that while these risk factors may be associated with cavernoma, they do not guarantee the development of the condition. If you have concerns about cavernoma or any other health condition, it's always best to consult with a healthcare professional for personalized advice and guidance.

Symptoms

The most common symptoms of cavernoma include:

  • Hemorrhage (bleeding)
  • Seizures
  • Headaches
  • Fatigue
  • Slurred speech
  • Double vision
  • Balance problems
  • Tremor
  • Memory problems
  • Poor concentration
  • Limb weakness or numbness
  • Loss of bladder control or bowel control

It's important to note that symptoms can vary depending on the location of the Cavernoma, such as in the brain, spinal cord, or eye. If you experience any concerning symptoms, it's recommended to consult with your healthcare professional for proper evaluation and diagnosis.

Diagnosis

To diagnose cavernoma, the following examinations, tests, and procedures are commonly performed:

  • Physical exam: The healthcare provider will ask about medical history and look for physical signs of a medical problem, such as pain, swelling, or the presence of masses in the body. This can help rule out other conditions that may have similar symptoms to a cavernoma.
  • Genetic testing: If there is family history, this may be done to find a genetic variant that can cause a cavernoma.
  • Imaging studies: Imaging techniques like X-rays or MRI scans can help visualize the cavernous malformation.
  • Follow-up visits: Regular check-ups scheduled once a year for several years can monitor the progression of the condition.

Remember that these examinations and procedures should be discussed with your healthcare provider. They will guide you on which tests are appropriate for your individual situation.

Treatment Options

The goals of treatment for a cavernoma are to reduce symptoms, prevention of complications and improve surgical outcomes. Treatments may include:

  • Surgery: This is often recommended as the preferred treatment method for cavernoma to prevent complications. Microsurgery involves the surgical removal of the cavernoma, where total removal decreases chances of recurrence.
  • Medications: There are no specific medications used to treat a cavernoma. However, your doctor may prescribe medications to manage symptoms or prevent complications. This could include medications for pain management or antiepileptic drugs if seizures occur.
  • Health behavior changes: Making certain lifestyle changes can help manage symptoms and reduce the risk of complications from Cavernoma. These may include maintaining a healthy diet, engaging in regular exercise, managing stress levels, and avoiding activities that could increase the risk of bleeding or injury.

It's important to note that treatment options should be discussed with a healthcare professional who can provide personalized advice based on individual circumstances. Medication dosing may be affected by many factors. Check with your health care professional about dosing for your individual situation. Other side effects can occur. Check with your health care professional or read the information provided with your medication for additional side effect information.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401103
Outcome of intracerebral cavernoma treated by Gamma Knife radiosurgery based on a double-blind assessment of treatment indication.
The benefit and the risk profile of Gamma Knife radiosurgery (GKRS) for intracerebral cavernoma remains incompletely defined in part due to the natural history of low incidence of bleeding and spontaneous regression of this vascular malformation. In this study, we retrieved cases from a prospectively collected database to assess the outcome of intracerebral cavernoma treated with GKRS using a double blinded review process for treatment.
PubMed Central
2021-08-28
/en/sources/healthline-what-is-a-cavernous-hemangioma
What Is a Cavernous Hemangioma?
Healthline
2022-10-24
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880495
Management of Central Nervous System Cavernomas: An Experience of the Department of Neurosurgery at the Ibn Tofail Hospital, Mohammed VI University Hospital.
Central nervous system cavernomas are congenital vascular anomalies posing a challenge not only in their diagnosis but also in their therapeutic management. The latter depends largely on their natural evolution and specifically their hemorrhagic potential.
PubMed Central
2022-12-27
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742471
Spinal Cavernomas: Outcome of Surgically Treated 10 Patients.
We report the preoperative and postoperative findings and also neurological follow-up results from 10 spinal cavernoma patients treated in our clinic. Several representative cases are presented in terms of clinical features, imaging results, and surgical outcomes.
PubMed Central
2017-12-20
https://rarediseases.info.nih.gov/diseases/13641/familial-cerebral-cavernous-malformation/diagnosis
Familial cerebral cavernous malformation - Getting a Diagnosis - Genetic and Rare Diseases Information Center
Learn about diagnosis and specialist referrals for Familial cerebral cavernous malformation.
Genetic and Rare Diseases Information Center - National Center for Advancing Translational Sciences
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898922
A murine model of cerebral cavernous malformations with acute hemorrhage.
Cavernomas are multi-lumen and blood-filled vascular malformations which form in the brain and the spinal cord. They lead to hemorrhage, epileptic seizures, neurological deficits, and paresthesia. An effective medical treatment is still lacking, and the available murine models for cavernomas have several limitations for preclinical studies. These include disease phenotypes that differ from human diseases, such as restriction of the lesions to the cerebellum, and absence of acute hemorrhage. Additional limitations of current murine models include rapid development of lesions, which are lethal before the first month of age. Here, we have characterized a murine model that recapitulates features of the human disease: lesions develop after weaning throughout the entire CNS, including the spinal cord, and undergo acute hemorrhage. This provides a preclinical model to develop new drugs for treatment of acute hemorrhage in the brain and spinal cord, as an unmet medical emergency for patients with cavernomas.
PubMed Central
2022-02-18
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414059
Feasibility of comparing medical management and surgery (with neurosurgery or stereotactic radiosurgery) with medical management alone in people with symptomatic brain cavernoma - protocol for the Cavernomas: A Randomised Effectiveness (CARE) pilot trial.
The top research priority for cavernoma, identified by a James Lind Alliance Priority setting partnership was 'Does treatment (with neurosurgery or stereotactic radiosurgery) or no treatment improve outcome for people diagnosed with a cavernoma?' This pilot randomised controlled trial (RCT) aims to determine the feasibility of answering this question in a main phase RCT.
PubMed Central
2023-08-09
https://rarediseases.info.nih.gov/diseases/10750/diffuse-cavernous-hemangioma-of-the-rectum/diagnosis
Diffuse cavernous hemangioma of the rectum - Getting a Diagnosis - Genetic and Rare Diseases Information Center
Learn about diagnosis and specialist referrals for Diffuse cavernous hemangioma of the rectum.
Genetic and Rare Diseases Information Center - National Center for Advancing Translational Sciences
https://rarediseases.info.nih.gov/diseases/1204/cerebral-cavernous-malformation/diagnosis
Cerebral cavernous malformation - Getting a Diagnosis - Genetic and Rare Diseases Information Center
Learn about diagnosis and specialist referrals for Cerebral cavernous malformation.
Genetic and Rare Diseases Information Center - National Center for Advancing Translational Sciences
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827309
Long-term outcome and quality of life after CNS cavernoma resection: eloquent vs. non-eloquent areas.
The aim of this study is to analyze the long-term quality of life after surgery of cavernoma. A monocentric retrospective study was conducted on 69 patients with cavernoma treated microsurgically between 2000 and 2016. The eloquence was adopted from Spetzler-Martin definition. A most recent follow-up was elicited between 2017 and 2019, in which the quality of life (QoL) was evaluated with the Short Form-12 questionnaire (SF12). Forty-one lesions were in eloquent group (EG), 22 in non-eloquent group (NEG), 3 in orbit, and 3 in the spinal cord. Postoperative worsening of the modified Rankin scale (mRS) occurred in 19.5% of cases in EG versus 4.5% in NEG. After a mean follow-up of 6.5 years (SD 4.6), the neurological status was better or unchanged compared to baseline in 85.4% of EG and 100% of NEG. Regarding QoL assessment of 44 patients (EG n = 27, NEG n = 14) attended the last follow-up. Patients after eloquent cavernoma resection reported a non-inferior QoL in most SF12 domains (except for physical role) compared to NEG. However, they reported general health perception inferior to norms, which was affected by the limited physical and emotional roles. At a late follow-up, the surgical morbidity was transient in the NEG and mostly recovered in the EG. The QoL comparison between eloquent and non-eloquent cavernomas created interesting and new data after prolonged follow-up. These results add value for decision-making as well as patient counseling for future encountered cases. Preoperative evaluation of QoL is recommended for future studies to assess QoL dynamics.
PubMed Central
2021-06-23